MFS Medifocus Inc

(NOT FOR DISSEMINATION IN THE UNITED STATES OF AMERICA)

Further to its news release of April 8, 2011, Medifocus Inc. (Medifocus or the
Company) (TSX VENTURE:MFS)(OTCQX:MDFZF) announces that it has awarded 3,000,000
shares (the Shares) to its directors and officers as follows: 




----------------------------------------------------------------------------
       Officer/Director               Position              Number of       
                                                      Common Shares Granted 
----------------------------------------------------------------------------
Grant B. Walsh                Chairman of the Board                  450,000
----------------------------------------------------------------------------
Joseph S.C. Chan              Director                               250,000
----------------------------------------------------------------------------
Dr. Augustine P.Y. Chow       Director                               150,000
----------------------------------------------------------------------------
Ernie Eves                    Director                               500,000
----------------------------------------------------------------------------
Joe K.F. Tai                  Director                               350,000
----------------------------------------------------------------------------
Dr. Augustine Y. Cheung       President and CEO                      600,000
----------------------------------------------------------------------------
John Mon                      Chief Operating Officer                500,000
----------------------------------------------------------------------------
Mirsad Jakubovic              Chief Financial Officer                200,000
----------------------------------------------------------------------------
Total                                                              3,000,000
----------------------------------------------------------------------------



The Shares were issued, at a deemed price of $0.18 per Share, in lieu of a
portion of the directors and officers cash compensation as well as in
recognition of their continued service to the Company. The awards permit the
directors and officers to participate in the success of the Company and is
intended to focus the management team on achieving the Company's strategic goals
and increasing shareholder value. The shareholders of the Company had previously
approved the issuance at the Company's last annual meeting of shareholders
including approval by a majority of disinterested shareholders. 


Medifocus owns a patented microwave focusing technology platform (the Adaptive
Phased Array (APA) technology), which can precisely target and control microwave
energy to cause heating in cancerous tumors anywhere in the body reliably and
repeatedly. The ability to target tumors with a precision controlled dose of
heat can be used to destroy tumors at higher temperatures, to treat tumors in
combination with chemotherapy and/or radiation at moderate temperatures for
increased effectiveness and reduced toxicity and to trigger the targeted release
of therapeutic drugs and genes at tumor sites at lower temperatures. While the
core technology has been licensed from the Massachusetts Institute of
Technology, Medifocus has further refined the precision of the microwave
focusing and control ability and developed a commercial system dedicated
exclusively for the treatment of Breast Cancer. With the acquisition of
Prolieve, Medifocus now owns in addition, a revenue generating commercial BPH
heat treatment product generating cash flow to support the development and
commercialization of other catheter based or APA based external focused heat
systems for targeted thermotherapy of deep seated tumors anywhere in the body.
Please visit www.medifocusinc.com for more details.

Grafico Azioni Medifocus (TSXV:MFS)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Medifocus (TSXV:MFS)
Storico
Da Giu 2023 a Giu 2024